Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT02884648
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Fallopian Tube Cancer
  • Malignant Neoplasms of Female Genital Organs
  • Ovarian Cancer
  • Primary Peritoneal Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    15 mg/kg by vein on Day 1 of every 21-day study cycle.

Study Details

The goal of this clinical research study is to learn if Avastin (bevacizumab) can help to control ovarian, fallopian, or primary peritoneal cancer that has been found during second-look surgery.

Key Dates

First listed
Aug 31, 2016
Start date
Nov 15, 2016
Status verified
Feb 2026
Primary completion
Feb 2, 2027
Completion
Feb 2, 2027

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab
    Participants receive Bevacizumab by vein on Day 1 of every 21-day study cycle, for as long as study doctor thinks it is in participant's best interest.

Primary Outcome Measure

Progression-Free Survival (PFS) of Participants with Positive Second-Look Findings Treated with Bevacizumab [ Time Frame: 63 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
University of Texas MD Anderson Cancer Center· Houston, TX

Related Studies